Acne vulgaris: management-/-National Institute for Health and Care Excellence: Guidelines 2023[Dec]; ä (ä): ä PMID34424628show ga
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing. In December 2023, we clarified our recommendations on oral isotretinoin treatment in line with the 2023 MHRA advice on the introduction of new safety measures. See the update information for more details. This guideline was commissioned by NICE and developed in partnership with the Royal College of Obstetricians and Gynaecologists (RCOG). NICE worked with the British Association of Dermatologists (BAD) to develop this guideline. WHO IS IT FOR? Healthcare professionals providing NHS-commissioned services. Commissioners of services. People with acne vulgaris, their families and carers.